The U.S. pharmaceutical market is at a critical inflection point in early 2026. For decades, the industry has operated within a framework that, while fostering significant innovation, has also ...

In today's Pharmaceutical Executive Daily, President Trump signs an executive order imposing 100% tariffs on imported ...

The Trump administration has also pushed back against Covid vaccine recommendations, and the FDA toughened its requirements ...

Khedkar was elected CEO of ZS in July 2021. Prior to assuming the role, he led the firm’s global pharmaceuticals practice for ...

Earlier this year, PacBio announced a collaboration with global rare disease genomics program iHope (part of the Genetic ...

When the bubble bursts, the tools that survive will not be the ones that generated the best demos. They will be the ones ...

In today’s Pharmaceutical Executive Daily, leadership turnover continues across key federal health agencies under the Trump ...

In today's Pharmaceutical Executive Daily, the Trump administration delays its appeal of the federal ruling blocking RFK ...

The deal continues Shionogi’s streak of acquisitions to begin 2026, as the company began the year acquiring $2.1 Billion ViiV ...

Agencies such as FDA, Centers for Disease Control (CDC), Health and Human Services (HHS), and The Center for Drug Evaluation ...

Soley Therapeutics’ co-founder and CEO Yerem Yeghiazarians, MD, spoke with Pharmaceutical Executive about the unique approach ...

Most importantly, pharmaceutical companies that negotiated agreements with the Trump administration for its Most Favored ...